The #NuCrew had three stellar additions this summer: thank you to Project Onramp for connecting us with our interns, Genevieve Hayes, Alexia Walters, and Marcela Villalta! We are grateful for your hard work and enthusiasm and look forward to seeing all that you will accomplish in your careers! 🌟
Nuvalent, Inc.
Biotechnology Research
Cambridge, Massachusetts 4,658 followers
#PreciselyTargetedTherapies for patients with cancer
About us
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
- Website
-
https://www.nuvalent.com/
External link for Nuvalent, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
One Broadway 14th Floor
Cambridge, Massachusetts 02142, US
Employees at Nuvalent, Inc.
Updates
-
Today we report our Q2 2024 financial results, highlighting pipeline progress and reinforcing anticipated milestones. We look forward to sharing data and development updates from our parallel lead programs for ROS1+ and ALK+ NSCLC at the ESMO - European Society for Medical Oncology Congress and at our conference call on September 14th! Read more about our updates here: https://lnkd.in/ewfdVUcF #ESMO24 #oncology #biotech
-
📣 The #NuCrew is hiring! We are on the lookout for a Director / Senior Director, Biostatistics! 👀 Learn more about this role and other new opportunities here: https://lnkd.in/eGq46agn #NuTalent #hiring #biotech
-
-
For #WorldLungCancerDay, join us in honoring advocacy organizations who work tirelessly on behalf of patients and their loved ones. Your work is instrumental in raising awareness of the continued research and innovation that is critical for patient impact. #WLCD24 #lungcancer
-
-
📣 Our 3rd program, NVL-330, is now in clinical development! Learn more about HEROEX-1, our Phase 1a/1b clinical trial of NVL-330 for pre-treated patients with HER2-altered #NSCLC, now open and enrolling. https://lnkd.in/eXn_TH7G #HER2 #oncology #biotech
-
-
We’re heading to Nashville to participate in this year’s ALK Positive Inc. Summit! This weekend, we’ll connect with experts, patients and caregivers as we explore the latest in ALK+ NSCLC research and cancer care. Register to join virtually: https://bit.ly/3W4oIkM #StrongerTogether #ALKSummit24 #LungCancer
-
-
✈️ Join us in Barcelona at this year’s ESMO - European Society for Medical Oncology Congress for updated clinical and preclinical data for our ROS1-selective inhibitor, zidesamtinib, and a clinical data update for our ALK-selective inhibitor, NVL-655! Learn more: https://lnkd.in/eENE_MCd #ESMO24 #biotech #oncology #NSCLC
-
-
We are delighted to announce Henry Pelish’s promotion to Chief Scientific Officer, reflecting his significant contributions at Nuvalent! A member of the #NuCrew from the start, Henry’s vision and leadership have helped shape our approach and fuel our pipeline of novel, precisely targeted kinase inhibitors. Read more here: https://lnkd.in/d8dHHSjh #biotech #oncology $NUVL #leadership
-
-
The #NuCrew had a blast participating in Bio-Ball 2024 to support Special Olympics Massachusetts — and we’re already practicing for next year’s tournament! 🏀
-